Appropriateness of Switches from Prescription to Over-the-Counter Drug Status. Influence of Demographic and Practice Characteristics on Pharmacist Decision Making

NSAID Rx-to-OTC switches: FDA is requiring lowest effective dose studies. Pink Sheet 1990; 52 (February 26): 5–8.

OTC analgesic advertising expenditures dropped to 13.1%. Pink Sheet 1990; 52 (March 12): T&G13–14.

P&G enters antacid market at the top: Rorer's Maalox obtained. Pink Sheet 1990; 52 (March 19): 14–15.

Gannon K . Rx-to-OTC switches raise a new call for third class. Drug Top 1989; 133 (October 16): 48.

Laverty RF White JP . Rx-to-OTC: Where's the trend taking pharmacy? Drug Top 1983; 127 (November 7): 38–47.

91% of RPhs urge curb on Rx drugs switched to OTC. Am Drug 1984; 189: 18.

Interim “3rd class” for drugs switched to OTC is backed by 50% of pharmacists. Am Drug 1985; 191: 14.

Madhavan S Schondelmeyer SW . Pharmacists' evaluations of the nonprescription availability of metaproterenol, cimetidine, ibuprofen, and nystatin. Am J Hosp Pharm 1989; 46: 2486–92.

Pathak DS Meinhold JM Fisher DJ . Research design: Sampling techniques. Am J Hosp Pharm 1980; 37: 998–1003.

Codling MD . The over-the-counter industry: A quiet revolution. Spectrum Pharmaceuticals: Products and technologies. Arthur D. Little Resources, 1987:2–11.

OTC drug market annual growth rate of 4% is due to Rx-to-OTC switches. Pink Sheet 1987; 50 (January 5): T&G 2.

Mackowiak J Gagnon JP . Rx-to-OTC: Impact on pharmacy profits—two case studies. NACDS funded project 1985:11.